FHIR Release 3 (STU) CI-Build

This page is part of the FHIR Specification (v3.0.2: STU 3). The current version which supercedes this version is 5.0.0 . For a full list Continuous Integration Build of available versions, see FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions . Page versions: R5 R4B R4 R3

Plandefinition-example-kdn5-simplified

Example PlanDefinition/KDN5 (Narrative)

Maturity Level : N/A
Responsible Owner: Clinical Decision Support Work Group Ballot Standards Status : Informative Compartments : Not linked to any No defined compartments

This is the narrative for the resource. See also the XML or , JSON or Turtle format. This example conforms to the profile PlanDefinition .

National Comprehensive Cancer Network

Chemotherapy Order Template

Kidney Cancer

Gemcitabine/CARBOplatin

KDN5

INDICATION:

Metastatic or Relapsed – Collecting Duct/Medullary Subtypes

REFERENCES:

  1. NCCN Guidelines Guidelines® for Kidney Cancer. V.3.2015.
  2. Oudard S, et al. J Urol . 2007;177(5):1698-702. a

NCCN SUPPORTIVE CARE:

  1. Emetic Risk:
    Day 1 Moderate
    Day 8 Low
  2. Fever Neutropenia Risk:
    Refer to NCCN Guidelines for Myeloid Growth Factors. V.2.2014

CHEMOTHERAPY REGIMEN

21-day cycle for 6 cycles

  • Gemcitabine 1250 mg/m 2 IV over 30 minutes on Days 1 and 8
  • CARBOplatin AUC 5 IV over 30 minutes on Day 1

 

Other examples that reference this example: MedicationAdministration/IV Admixture RequestGroup/KDN5 Example  

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.